Mary Wilson
Well-known member
Published:September 15, 2023
DOI: https://doi.org/10.1016/S1473-3099(23)00376-6
Michael A Moso, FRACP, Chuan K Lim, PhD, Eloise Williams, FRACP, Caroline Marshall, PhD, Prof James McCarthy, FRACP, Prof Deborah A Williamson, PhD
Summary
There have been significant advances in the prevention and management of Ebola virus disease (EVD) caused by Zaire Ebola virus (ZEBOV), including the development of two effective vaccines, rVSV-ZEBOV and Ad26.ZEBOV/MVA-BN-Filo. In addition, ZEBOV monoclonal antibodies have become first-line therapy for EVD. However, the 2022–23 outbreak of Sudan Ebola virus (SUDV) in Uganda has highlighted the gap in current therapies and vaccines, whose efficacy is uncertain against non-ZEBOV species. Health-care and laboratory staff working in EVD treatment centres or Ebola virus diagnostic and research laboratories face unique risks relating to potential occupational exposure to Ebola viruses. Given the substantial morbidity and mortality associated with EVD, facilities should have strategies in place to manage occupational exposures, including consideration of post-exposure therapies. In this Review, we discuss currently available evidence for prevention and post-exposure prophylaxis of EVD, including therapies currently under evaluation for SUDV.
$$ To read this article in full you will need to make a payment $$
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00376-6/fulltext?rss=yes
DOI: https://doi.org/10.1016/S1473-3099(23)00376-6
Michael A Moso, FRACP, Chuan K Lim, PhD, Eloise Williams, FRACP, Caroline Marshall, PhD, Prof James McCarthy, FRACP, Prof Deborah A Williamson, PhD
Summary
There have been significant advances in the prevention and management of Ebola virus disease (EVD) caused by Zaire Ebola virus (ZEBOV), including the development of two effective vaccines, rVSV-ZEBOV and Ad26.ZEBOV/MVA-BN-Filo. In addition, ZEBOV monoclonal antibodies have become first-line therapy for EVD. However, the 2022–23 outbreak of Sudan Ebola virus (SUDV) in Uganda has highlighted the gap in current therapies and vaccines, whose efficacy is uncertain against non-ZEBOV species. Health-care and laboratory staff working in EVD treatment centres or Ebola virus diagnostic and research laboratories face unique risks relating to potential occupational exposure to Ebola viruses. Given the substantial morbidity and mortality associated with EVD, facilities should have strategies in place to manage occupational exposures, including consideration of post-exposure therapies. In this Review, we discuss currently available evidence for prevention and post-exposure prophylaxis of EVD, including therapies currently under evaluation for SUDV.
$$ To read this article in full you will need to make a payment $$
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00376-6/fulltext?rss=yes